855-226-9991 [email protected]

News

Cardio Diagnostics Announces Headquarters Relocation to Chicago

Cardio Diagnostics Announces Headquarters Relocation to Chicago

Pioneer of AI-driven, epigenetics-based clinical tests for cardiovascular disease moves for Chicago's thriving biotech ecosystem and access to talent and resources CHICAGO, May 25, 2022 – Cardio Diagnostics, Inc., ("Cardio Diagnostics"), a company pioneering...

Cardio Diagnostics Jan 2021 Press Release

Cardio Diagnostics Jan 2021 Press Release

Cardio Diagnostics’ Epi+Gen CHD at-home sampling kit: Potential patients fill out a screening questionnaire that is reviewed by a board-certified clinician. If eligible for the test, a sampling kit is sent to their home. After the sample is collected, it is shipped...

Cardio Diagnostics receives a Phase I NIH SBIR

Cardio Diagnostics receives a Phase I NIH SBIR

Cardio Diagnostics received $225K in National Institutes of Health (NIH) funding to further develop our integrated genetic-epigenetic coronary heart disease risk screening technology.